Effi 7

Drug Profile

Effi 7

Alternative Names: Anti CD127 monoclonal antibody - OSE Immunotherapeutics; Anti interleukin-7 receptor-α monoclonal antibody - OSE Immunotherapeutics; Effi-7; IL-7 receptor antagonist - OSE Immunotherapeutics; Interleukin-7 receptor antagonist - OSE Immunotherapeutics

Latest Information Update: 29 Dec 2016

Price : $50

At a glance

  • Originator Effimune
  • Developer INSERM; OSE Immunotherapeutics; PX Therapeutics
  • Class Monoclonal antibodies
  • Mechanism of Action Interleukin 7 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute lymphoblastic leukaemia; Inflammation; Transplant rejection; Ulcerative colitis
  • Research Sjogren's syndrome

Most Recent Events

  • 27 Dec 2016 Effi-7 licensed to Servier Pharmaceuticals worldwide
  • 27 Dec 2016 Early research in Sjogren's syndrome in France (Parenteral)
  • 27 Dec 2016 OSE Immunotherapeutics plans a phase II trial for Ulcerative colitis in France
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top